text
"['\n1. 요약재무정보\n하기 연결재무정보 및 재무정보는 한국채택국제회계기준에 따라 작성되었으며,제61기(전전기)는 종전 기준서인 K-IFRS 1017호에 따라 작성 되었습니다.또한 제63기 연결재무정보 및 재무정보는 주주총회 승인 전 재무제표로 향후 정기주주총회에서 재무제표 승인 관련 안건이 부결되거나 수정이 발생한 경우 정정보고서를 통해 그 내용 및 사유를 반영할 예정입니다.\n1) 요약연결재무정보\n국제약품(주) 및 종속기업\xa0 \xa0\n(단위 : 원)\n구 분\n제63기\n제62기\n제61기\n[유동자산]\n49,940,201,956\xa0\n61,135,035,867\xa0\n54,559,369,036\n-현금및현금성자산\n4,013,014,774\xa0\n7,448,034,125\xa0\n3,658,579,316\n-매출채권\n20,250,681,477\xa0\n20,667,104,826\xa0\n24,356,918,543\n-재고자산\n21,651,887,423\xa0\n16,595,366,817\xa0\n14,183,645,117\n-기타유동자산\n4,024,618,282\xa0\n16,424,530,099\xa0\n12,360,226,060\n[비유동자산]\n95,685,349,934\xa0\n73,458,578,230\xa0\n71,675,526,598\xa0\n-유형자산\n84,882,176,864\xa0\n64,359,978,411\xa0\n61,277,407,372\xa0\n-무형자산\n1,492,236,263\xa0\n1,677,484,748\xa0\n1,872,761,740\xa0\n-투자부동산\n3,488,952,649\xa0\n4,093,469,130\xa0\n4,238,926,338\xa0\n-기타비유동자산\n5,821,984,158\xa0\n3,327,645,941\xa0\n4,286,431,148\xa0\n자산총계\n145,625,551,890\xa0\n134,593,614,097\xa0\n126,234,895,634\xa0\n[유동부채]\n55,357,616,964\xa0\n59,250,771,507\xa0\n48,199,751,500\xa0\n[비유동부채]\n19,769,071,069\xa0\n14,388,889,463\xa0\n9,336,991,512\xa0\n부채총계\n75,126,688,033\xa0\n73,639,660,970\xa0\n57,536,743,012\xa0\n[자본금]\n18,400,520,000\xa0\n18,400,520,000\xa0\n18,057,107,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,335,099,371\xa0\n21,480,876,507\xa0\n22,177,699,694\xa0\n[기타자본항목]\n15,816,353,383\xa0\n16,683,166,546\xa0\n16,695,392,877\xa0\n[이익잉여금]\n3,058,916,238\xa0\n492,983,140\xa0\n7,870,638,339\xa0\n지배기업소유주지분\n70,482,457,184\xa0\n60,929,114,385\xa0\n68,672,406,102\xa0\n비지배지분\n16,406,673\xa0\n24,838,742\xa0\n25,746,520\xa0\n자본총계\n70,498,863,857\xa0\n60,953,953,127\xa0\n68,698,152,622\xa0\n부채와자본총계\n145,625,551,890\xa0\n134,593,614,097\xa0\n126,234,895,634\xa0\n매출액\n130,394,720,787\xa0\n111,121,601,008\xa0\n107,681,163,418\xa0\n영업이익\n6,041,374,040\xa0\n5,570,756,961\xa0\n3,287,017,509\xa0\n당기순이익(손실)\n2,194,568,946\xa0\n(4,761,811,946)\n2,182,873,368\xa0\n\xa01.지배기업소유주지분\n2,203,001,015\xa0\n(4,760,904,168)\n2,192,621,154\xa0\n\xa02.비지배지분\n(8,432,069)\n(907,778)\n(9,747,786)\n기타포괄손익\n7,350,341,784\xa0\n(2,384,442,638)\n(558,114,444)\n당기총포괄이익(손실)\n9,544,910,730\xa0\n(7,146,254,584)\n1,624,758,924\xa0\n\xa01.지배기업소유주지분\n9,553,342,799\xa0\n(7,145,346,806)\n1,634,506,710\xa0\n\xa02.비지배지분\n(8,432,069)\n(907,778)\n(9,747,786)\n주당순이익(손실)\n126\xa0\n(272)\n125\n연결에 포함된 회사수\n1\xa0\n1\n1\n<종속기업 재무정보 요약>\n(2020년)\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,592,178\n307,625\n3,960,265\n(158,101)\n(2019년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,510,709\n465,726\n2,429,926\n(17,021)\n(2018년)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n\xa0(단위:천원)\n회사명\n총자산\n자기자본\n매출액\n당기순손익\n케이제이케어(주)\n1,171,994\n482,747\n1,533,821\n(182,771)\n2) 요약재무정보\n국제약품(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0\n(단위 : 원)\n구 분\n제63기\n제62기\n제61기\n[유동자산]\n49,174,515,891\xa0\n60,161,878,936\xa0\n53,591,579,999\xa0\n-현금및현금성자산\n3,658,329,420\xa0\n7,218,053,324\xa0\n3,343,108,063\xa0\n-매출채권\n19,929,859,420\xa0\n20,233,344,301\xa0\n24,069,101,895\xa0\n-재고자산\n21,569,134,807\xa0\n16,296,426,007\xa0\n13,837,452,079\xa0\n-기타유동자산\n4,017,192,244\xa0\n16,414,055,304\xa0\n12,341,917,962\xa0\n[비유동자산]\n94,837,294,329\xa0\n72,940,313,200\xa0\n71,518,152,473\xa0\n-유형자산\n84,465,524,125\xa0\n64,214,202,193\xa0\n61,144,981,394\xa0\n-무형자산\n1,489,062,824\xa0\n1,674,311,309\xa0\n1,869,588,301\xa0\n-투자부동산\n3,592,170,673\xa0\n4,093,469,130\xa0\n4,238,926,338\xa0\n-기타비유동자산\n5,290,536,707\xa0\n2,958,330,568\xa0\n4,264,656,440\xa0\n자산총계\n144,011,810,220\xa0\n133,102,192,136\xa0\n125,109,732,472\xa0\n[유동부채]\n55,168,831,048\xa0\n59,080,611,261\xa0\n48,116,428,802\xa0\n[비유동부채]\n19,415,080,745\xa0\n14,278,918,866\xa0\n9,281,215,987\xa0\n부채총계\n74,583,911,793\xa0\n73,359,530,127\xa0\n57,397,644,789\xa0\n[자본금]\n18,400,520,000\xa0\n18,400,520,000\xa0\n18,057,107,000\xa0\n[주식발행초과금]\n3,871,568,192\xa0\n3,871,568,192\xa0\n3,871,568,192\xa0\n[기타포괄손익누계액]\n29,236,392,939\xa0\n21,480,876,507\xa0\n22,177,699,694\xa0\n[기타자본항목]\n15,989,697,310\xa0\n16,856,510,473\xa0\n16,868,736,804\xa0\n[이익잉여금]\n1,929,719,986\xa0\n(866,813,163)\n6,736,975,993\xa0\n자본총계\n69,427,898,427\xa0\n59,742,662,009\xa0\n67,712,087,683\xa0\n자본과부채총계\n144,011,810,220\xa0\n133,102,192,136\xa0\n125,109,732,472\xa0\n종속·관계·공동기업\n투자주식의 평가방법\n원가법\n원가법\n원가법\n매출액\n126,514,615,485\xa0\n108,709,297,057\xa0\n106,305,202,738\xa0\n영업이익\n6,195,143,340\xa0\n5,594,782,551\xa0\n2,978,856,968\xa0\n당기순이익(손실)\n2,433,601,066\xa0\n(4,987,038,125)\n1,698,290,969\xa0\n기타포괄손익\n7,251,635,352\xa0\n(2,384,442,638)\n(558,114,444)\xa0\n당기총포괄손익\n9,685,236,418\xa0\n(7,371,480,763)\n1,140,176,525\xa0\n주당순이익(손실)\n139\xa0\n(285)\n97\n']"
